Pharsight

1. List of Aubagio drug patents

Application	Filing Date	Opposition Party	Legal Status
EP10752585A	2018-01-04	Pentafarma Sociedade Técnico-Medicinal S.A.	Revoked
EP10752585A	2017-12-29	Wuesthoff & Wuesthoff Patentanwälte PartG mbB	Revoked
EP10752585A	2017-12-19	Cooke, Richard	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410	SANOFI AVENTIS US	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis	Sep, 2026 (3 years from now)
US6794410 (Pediatric)	SANOFI AVENTIS US	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis	Mar, 2027 (3 years from now)
US8802735	SANOFI AVENTIS US	(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability	Sep, 2030 (7 years from now)
US8802735 (Pediatric)	SANOFI AVENTIS US	(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability	Mar, 2031 (7 years from now)
US9186346	SANOFI AVENTIS US	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients	Feb, 2034 (10 years from now)
US9186346 (Pediatric)	SANOFI AVENTIS US	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients	Aug, 2034 (11 years from now)

Exclusivity	Exclusivity Expiration
M (M)	Apr 30, 2024
Pediatric Exclusivity (PED)	Oct 30, 2024

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose

Dosage: TABLET;ORAL